CLINICAL TRIAL
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

The effectiveness of cognitive behavioral therapy on changing eating disorder symptoms and psychopathology of 32 anorexia nervosa patients at hospital discharge and one year follow-up.

BACKGROUND: This study aims to assess changes in core eating disorder psychopathology (Eating Attitudes Test, EAT; Eating Disorders Inventory-2, EDI-2), depression (Hamilton Rating Scale, HRSD; Beck Depression Inventory, BDI) and general psychopathology (MMPI-2) after inpatient treatment and one-year follow-up among patients diagnosed with anorexia.

METHODS: Thirty-two patients were treated for anorexia nervosa on an inpatient unit, and were assessed before and after treatment. The inpatient milieu was designed to use cognitive therapy as the primary therapeutic intervention, along with weight restoration.

RESULTS: At discharge, all patients displayed significant change in core eating disorder psychopathology in their depressive symptoms, as well as in general aspects of psychopathology. At one-year follow-up, changes in some areas of core eating disorder psychopathology and depressive symptoms continued to be significantly different than from admissions.

CONCLUSIONS: The combination of CBT and weight restoration can significantly reduce eating disorder symptoms, depression, and general psychopathology during hospitalization, with some sustained benefit over a one year period. Future research is needed to identify the effect of CBT on anorexia nervosa during a wide variety of treatment settings. Also, research must focus on the influence of outpatient treatment in the outcome of anorexia nervosa.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app